EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

SeaStar Medical Holding Corporation (ICU) fair value: what the stock is really worth

As of Oct 15, 2026: fair value of SeaStar Medical Holding Corporation $1.87, price $3.06, upside -38.9%, quality 45 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US

SM SeaStar Medical Holding Corporation logo Thin data Oct 13, 2026

SeaStar Medical Holding Corporation

ICU · US

Weakest SetupStrongly overvalued and low quality.

Our calculation puts a fair price 39% below what the stock costs today.

Low debt
Quality 45/100
Mixed Growth (revenue YoY +814.1 %/yr in USD)
Fair value $1.87 · Strongly overvalued (−38.9%)
Negative free cash flow
Trails peers (3/8)
Narrow moat 8/100 · thin data
Thin data
Watch SeaStar Medical Holding Corporation for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$3,088 $2.21 Fair Value $1.87 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 13, 2026.

How to read this chart

60‑month range $2.21 – $3,088 · fair‑value band $1.23 – $2.34 · the $3.06 price screens above the $1.87 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 13, 2026.

Follow SeaStar Medical Holding in your weekly email

Every Wednesday you see whether SeaStar Medical Holding is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States.

Show moreShow less

The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis.

It also develops NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult patients with AKI; and other products in various therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease.

SeaStar Medical Holding Corporation was founded in 2007 and is headquartered in Denver, Colorado.

Stock analysis

SeaStar Medical Holding Corporation (ICU) currently trades at $3.06, while our model-based Fair Value estimate is $1.87, 38.9% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: $1.23 (bear) to $2.34 (bull), the price of $3.06 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

SeaStar Medical Holding Corporation reported revenue of $1.2M in FY2025 versus $0 in FY2021. Reported net income was −$12.2M in FY2025.

Key figures

Market cap $19.0M · P/S ratio 11.1 · EPS (TTM) $−3.09 · Return on equity −357% · Return on assets (EBIT) −399% · Operating margin −616% · Revenue (TTM) $1.7M · Revenue growth (YoY) +82.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 52% below its 52-week high and 38% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −39%, ICU screens richer than that median.

Fair Value models

Bear $1.23 Fair Value $1.87 Bull $2.34
Price $3.06 · Upside -38.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) $0.9900 $1.33 $1.98 54
All 1 models by family
Asset-Based
NCAV (Graham) $0.9900 $1.33 $1.98 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 45/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 3
How much profit the company makes from its sales and capital
Quality Growth 77
Are margins and returns getting better?
Cashflow 35
Do the profits arrive as real cash?
Financial strength 69
Debt, balance sheet and risk of trouble
Investment 50
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Momentum 8
Price trend of the last 3 to 12 months, does not count
Near the 52-week high 10
Distance to the 52-week high, does not count
New shares 50
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 28/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

ICU screens overvalued: fair value 39% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare SeaStar Medical Holding Corporation with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 603 stocks

Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 45 · Above median
Fair Value upside −38.9% · Above median
Profitability
Return on assets −85.8% · Bottom 25%
Growth and dividend
Revenue growth 82.0% · Top 25%
Balance sheet
Debt / equity 0.42× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.82× · Pricier than median
P/S (12 months) 11.09× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)79 · sector 97
DIVIDEND (yield)0 · sector 22

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $746.54 $1,275 +71% vs ICU
Vertex Pharmaceuticals Incorporated VRTX $510.08 $561.09 +10% vs ICU
argenx SE ARGX $825.03 $907.53 +10% vs ICU
Samsung Biologics Co 207940 1,219,000 KRW 1,340,900 KRW +10% vs ICU
WuXi Biologics (Cayman) Inc 2269 HK$52.65 HK$57.92 +10% vs ICU
CSL Limited CSL A$181.46 A$179.90 −1% vs ICU
Alnylam Pharmaceuticals, Inc ALNY $232.68 $217.88 −6% vs ICU
BeOne Medicines AG ONC $354.47 $280.94 −21% vs ICU
Celltrion, Inc 068270 180,400 KRW 74,519 KRW −59% vs ICU
Royalty Pharma plc RPRX $56.93 $19.01 −67% vs ICU

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

SeaStar Medical Holding Corporation · Fair Value
$1.87 −39%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "SeaStar Medical Holding Corporation Fair Value". https://www.fairvalue-calculator.com/stock/ICU

Frequently asked questions

Is SeaStar Medical Holding Corporation (ICU) overvalued or undervalued?
As of Oct 13, 2026, our model estimates a fair value of $1.87 versus a price of $3.06, about −39% upside (overvalued).
What is the fair value of ICU?
Our model-based fair value for SeaStar Medical Holding Corporation is $1.87 (as of Oct 13, 2026), built from audited fundamentals. The current price: $3.06.
What is the quality score of ICU?
SeaStar Medical Holding Corporation has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for SeaStar Medical Holding Corporation (ICU)?
Our model-based price target is the fair value of $1.87 (as of Oct 13, 2026) from 1 valuation models. Cautious scenario $1.23, optimistic scenario $2.34. It is a calculation from audited fundamentals, not an analyst target.
What is the SeaStar Medical Holding Corporation stock forecast for 2026?
Our models put fair value at $1.87, about −39% upside versus a price of $3.06 (overvalued). Cautious scenario $1.23, optimistic scenario $2.34. The calculation is refreshed regularly with new filings.
What is the revenue of SeaStar Medical Holding Corporation (ICU)?
SeaStar Medical Holding Corporation reported trailing-twelve-month revenue of about $1.7M (latest available figure, as of Oct 13, 2026).
What is the intrinsic value of SeaStar Medical Holding Corporation (ICU)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For SeaStar Medical Holding Corporation it is $1.87 per share (as of Oct 13, 2026), against a price of $3.06. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is SeaStar Medical Holding Corporation stock overvalued or undervalued in 2026?
As of Oct 13, 2026, ICU trades above its calculated fair value: price $3.06, fair value $1.87, a gap of about −39% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ICU?
No. The price is what the market pays today ($3.06); the fair value is what the company's own numbers justify ($1.87). For SeaStar Medical Holding Corporation the two are $1.19 per share apart. That gap is exactly why we show both numbers side by side.
How much is SeaStar Medical Holding Corporation worth?
The market values SeaStar Medical Holding Corporation at about $19.0M (market capitalisation, as of Oct 13, 2026). Per share that is $3.06; our models calculate a fair value of $1.87 per share.
What do the bullish and bearish scenarios say about ICU?
Our models span a range for SeaStar Medical Holding Corporation: cautious scenario $1.23, base $1.87, optimistic $2.34 per share (as of Oct 13, 2026, price $3.06). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of SeaStar Medical Holding Corporation (ICU)?
Balance-sheet figures for SeaStar Medical Holding Corporation (as of Oct 13, 2026): return on equity −356.9%, debt of 0.42 per unit of equity. They feed the Quality Score of 45/100, which measures business quality independently of the share price.
How far is ICU from its 52-week high?
SeaStar Medical Holding Corporation trades at $3.06, about 52% below its 52-week high of $6.37 and 38% above the low of $2.21 (as of Oct 15, 2026). Distance from the high says nothing about value: that is what the fair value of $1.87 is for.
Which stocks are comparable to SeaStar Medical Holding Corporation?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is SeaStar Medical Holding Corporation stock attractive at the current price?
The data as of Oct 13, 2026: price $3.06, calculated fair value $1.87 (−39%), Quality Score 45/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ICU calculated?
We run SeaStar Medical Holding Corporation through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $1.87, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.8 % above its aggregate fair value. SeaStar Medical Holding Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of SeaStar Medical Holding Corporation (ICU)?
The closing price on Oct 15, 2026 was $3.06. Our model-based fair value is $1.87, about −39% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with SeaStar Medical Holding Corporation right now?
The price sits above even our optimistic bull case ($2.34). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (45/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($1.23 to $2.34) leaves room in how you read the outcome.

Key figures of SeaStar Medical Holding Corporation

How large is the market capitalisation of SeaStar Medical Holding Corporation (ICU)?
The market capitalisation of SeaStar Medical Holding Corporation is $19.0M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of SeaStar Medical Holding Corporation (ICU)?
The price-to-sales ratio of SeaStar Medical Holding Corporation is 11.1 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of SeaStar Medical Holding Corporation (ICU)?
Earnings per share at SeaStar Medical Holding Corporation are $−3.09. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of SeaStar Medical Holding Corporation (ICU)?
The return on equity (ROE) of SeaStar Medical Holding Corporation is −357% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of SeaStar Medical Holding Corporation (ICU)?
On an EBIT basis the return on assets of SeaStar Medical Holding Corporation is −399% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of SeaStar Medical Holding Corporation (ICU)?
The operating margin of SeaStar Medical Holding Corporation is −616% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at SeaStar Medical Holding Corporation (ICU)?
Revenue at SeaStar Medical Holding Corporation is growing +82.0% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does SeaStar Medical Holding Corporation (ICU) generate?
The free cash flow of SeaStar Medical Holding Corporation is −$13.6M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does SeaStar Medical Holding Corporation (ICU) hold?
SeaStar Medical Holding Corporation holds more cash than debt, $11.5M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch SeaStar Medical Holding Corporation in the live analysis

One click puts SeaStar Medical Holding Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.